Skip to Content

Generic Name: Ceftaroline Fosamil
Class: Fifth Generation Cephalosporins
VA Class: AM119
Chemical Name: 4 - [2 - [[(6R,7R) - 2 - Carboxy - 7 - [[(2Z) - (ethoxyimino)[5 - (phosphonoamino) - 1,2,4 - thiadiazol - 3 - yl]acetyl]amino] - 8 - oxo - 5 - thia - 1 - azabicyclo[4.2.0]oct - 2 - en - 3 - yl]thio] - 4 - thiazolyl] - 1 - methyl - pyridinium, inner salt, monoacetate, monohydrate
Molecular Formula: C22H21N8O8PS4.C2H4O2.H2O
CAS Number: 866021-48-9

Introduction

Antibacterial; β-lactam antibiotic;1 5 6 7 fifth generation cephalosporin.5 6 7 8 27

Uses for Teflaro

Community-acquired Pneumonia

Treatment of community-acquired bacterial pneumonia (CABP, CAP) caused by susceptible Streptococcus pneumoniae (including cases with concurrent bacteremia), Staphylococcus aureus (methicillin-susceptible [oxacillin-susceptible] strains only), Haemophilus influenzae, Klebsiella pneumoniae, K. oxytoca, or Escherichia coli.1 3

For information regarding treatment of CAP, consult current IDSA clinical practice guidelines available at .30 31 32

Skin and Skin Structure Infections

Treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible S. aureus (including methicillin-resistant S. aureus [MRSA; also known as oxacillin-resistant S. aureus, ORSA], S. pyogenes (group A β-hemolytic streptococci, GAS), S. agalactiae (group B streptococci, GBS), E. coli, K. pneumoniae, or K. oxytoca.1 2

Some clinicians state that ceftaroline is one of several options for treatment of skin and skin structure infections caused by MRSA, including empiric treatment of surgical site infections in patients at high risk for MRSA (e.g., nasal colonization, prior MRSA infection, recent hospitalization, recent anti-infective therapy).43

For information regarding treatment of skin and skin structure infections, including infections caused by MRSA, consult current IDSA clinical practice guidelines available at .32 43

Teflaro Dosage and Administration

Administration

Administer by IV infusion.1

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Do not admix with or add to solutions containing other drugs.1

Reconstitution and Dilution

Must be reconstituted and further diluted prior to IV infusion.1

Reconstitute 400- or 600-mg single-use vials of ceftaroline fosamil by adding 20 mL of sterile water for injection, 0.9% sodium chloride, 5% dextrose, or lactated Ringer's injection to provide solution containing approximately 20 or 30 mg/mL, respectively.1 Mix vial gently to ensure complete dissolution;1 reconstitution should take <2 minutes.1

Dilute appropriate dose of reconstituted solution in 50–250 mL of the same diluent used for reconstitution, unless drug was reconstituted with sterile water, in which case use any compatible IV infusion solution (see Solution Compatibility under Stability) for further dilution.1

To prepare 600-mg dose in 50-mL infusion bag for use in adults, remove 20 mL of diluent from bag prior to injecting entire reconstituted contents of 600-mg vial;1 final concentration of infusion solution is approximately 12 mg/mL.1

To prepare 400-mg dose in 50-mL infusion bag for use in adults or pediatric patients 2 months of age or older weighing >33 kg, remove 20 mL of diluent from bag prior to injecting entire reconstituted contents of 400-mg vial;1 final concentration of infusion solution is approximately 8 mg/mL.1

To prepare dose in 50-mL infusion bag for use in pediatric patients 2 months of age or older weighing ≤33 kg, amount of diluent to be removed from bag and amount of reconstituted drug solution to be withdrawn from vial and added to diluent vary depending on child's age and weight.1 Final concentration should not exceed 12 mg/mL.1

Reconstituted and diluted solutions appear clear and light to dark yellow.1

Final solution in IV infusion bag should be used within 6 hours when stored at room temperature or within 24 hours when stored in refrigerator at 2–8°C.1

Rate of Administration

Administer by IV infusion over 5–60 minutes.1

Dosage

Available as ceftaroline fosamil monoacetate monohydrate; dosage expressed in terms of anhydrous ceftaroline fosamil.1

Pediatric Patients

Community-acquired Pneumonia
IV

2 months to <2 years of age: 8 mg/kg every 8 hours.1

2 years to <18 years of age weighing ≤33 kg: 12 mg/kg every 8 hours.1

2 years to <18 years of age weighing >33 kg: 400 mg every 8 hours or 600 mg every 12 hours.1

Manufacturer recommends treatment duration of 5–14 days in pediatric patients;1 duration depends on site and severity of infection and patient’s clinical and bacteriologic progress.1

Skin and Skin Structure Infections
IV

2 months to <2 years of age: 8 mg/kg every 8 hours.1

2 years to <18 years of age weighing ≤33 kg: 12 mg/kg every 8 hours.1

2 years to <18 years of age weighing >33 kg: 400 mg every 8 hours or 600 mg every 12 hours.1

Manufacturer recommends treatment duration of 5–14 days in pediatric patients;1 duration depends on site and severity of infection and patient’s clinical and bacteriologic progress.1

Adults

Community-acquired Pneumonia
IV

600 mg every 12 hours for 5–7 days.1

Duration depends on site and severity of infection and patient’s clinical and bacteriologic progress.1

Skin and Skin Structure Infections
IV

600 mg every 12 hours for 5–14 days.1

Duration depends on site and severity of infection and patient’s clinical and bacteriologic progress.1

Special Populations

Hepatic Impairment

Manufacturer makes no specific dosage recommendations;1 hepatic impairment not expected to have a clinically important effect on systemic clearance of the drug.1

Renal Impairment

Adults: Adjust dosage in those with Clcr ≤50 mL/minute, including patients undergoing hemodialysis.1 (See Table 1.)

Table 1. Ceftaroline Fosamil Dosage for Adults with Renal Impairment1

Clcr (mL/min)

Recommended Dosage

31–50

400 mg every 12 h

15–30

300 mg every 12 h

<15 or receiving hemodialysis

200 mg every 12 h; on hemodialysis days, give dose after hemodialysis

Pediatric patients: Dosage adjustments not needed if Clcr >50 mL/minute per 1.73 m2.1 Data insufficient to make dosage recommendations for those with Clcr <50 mL/minute per 1.73 m2.1

Geriatric Patients

Dosage adjustment not required based on age; may be required based on age-related changes in renal function.1 (See Renal Impairment under Dosage and Administration.)

Cautions for Teflaro

Contraindications

  • Known serious hypersensitivity to ceftaroline or other cephalosporins.1 (See Sensitivity Reactions under Cautions.)

Warnings/Precautions

Sensitivity Reactions

Hypersensitivity Reactions

Serious, sometimes fatal, hypersensitivity (anaphylactic) reactions and serious skin reactions reported in patients receiving β-lactam antibiotics.1 Anaphylaxis reported with ceftaroline.1

If hypersensitivity reaction occurs, discontinue the drug and initiate appropriate treatment and supportive measures.1

Cross-hypersensitivity

Partial cross-sensitivity occurs among β-lactam antibiotics.1 27

Prior to initiation of therapy, make careful inquiry concerning previous hypersensitivity reactions to ceftaroline, other cephalosporins, penicillins, or carbapenems.1 Contraindicated in patients hypersensitive to the drug or other cephalosporins;1 closely monitor patient if used in those allergic to penicillin or other β-lactams.1

Clostridium difficile-associated Diarrhea and Colitis (CDAD)

Treatment with anti-infectives alters normal colon flora and may permit overgrowth of Clostridium difficile.1 12 13 14 15 16

C. difficile infection (CDI) and C. difficile-associated diarrhea and colitis (CDAD; also known as antibiotic-associated diarrhea and colitis or pseudomembranous colitis) have been reported with nearly all systemic anti-infectives, including ceftaroline, and may range in severity from mild diarrhea to fatal colitis.1 12 13 14 15 16 C. difficile produces toxins A and B which contribute to development of CDAD;1 13 12 hypertoxin-producing strains of C. difficile are associated with increased morbidity and mortality since they may be refractory to anti-infectives and colectomy may be required.1

Consider CDAD if diarrhea develops during or after anti-infective therapy and manage accordingly.1 12 13 14 15 16 Obtain a careful medical history since CDAD may occur as late as 2 months or longer after anti-infective therapy is discontinued.1

If CDAD is suspected or confirmed, discontinue anti-infectives not directed against C. difficile whenever possible.1 12 14 15 16 Initiate appropriate supportive therapy (e.g., fluid and electrolyte management, protein supplementation), anti-infective therapy directed against C. difficile (e.g., metronidazole, vancomycin), and surgical evaluation as clinically indicated.1 12 13 14 15 16

Hematologic Effects

Neutropenia,33 leukopenia,1 and agranulocytosis1 34 reported during postmarketing experience.1 33 34

Seroconversion from negative to positive direct antiglobulin (Coombs’) tests reported in clinical trials in about 11% of adults and about 18% of pediatric patients receiving ceftaroline;1 no evidence of hemolytic anemia in these adult or pediatric patients.1

Consider drug-induced hemolytic anemia in patients who develop anemia during or after ceftaroline treatment; perform diagnostic studies, including direct antiglobulin test.1 If drug-induced hemolytic anemia is suspected, consider discontinuing ceftaroline and administer supportive treatment (e.g., transfusion) as clinically indicated.1

Selection and Use of Anti-infectives

To reduce development of drug-resistant bacteria and maintain effectiveness of ceftaroline and other antibacterials, use only for treatment of infections proven or strongly suspected to be caused by susceptible bacteria.1

When selecting or modifying anti-infective therapy, use results of culture and in vitro susceptibility testing.1 In the absence of such data, consider local epidemiology and susceptibility patterns when selecting anti-infectives for empiric therapy.1

Specific Populations

Pregnancy

Adequate data not available regarding use in pregnant women.1

Lactation

Not known whether distributed into human milk;1 possible effects of the drug on breast-fed infant or on milk production unknown.1

Consider benefits of breast-feeding and the importance of ceftaroline to the woman;1 also consider potential adverse effects on breast-fed infant from the drug or from underlying maternal condition.1

Pediatric Use

Safety and efficacy not established in pediatric patients <2 months of age.1

Safety and efficacy established for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in pediatric patients 2 months to <18 years of age.1 Use for treatment of these indications in this age group supported by evidence from adequate and well-controlled studies in adults and additional pharmacokinetic and safety data from pediatric trials.1

Data indicate clinical cure rates reported for treatment of community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections in children 2 months to <18 years of age are similar to those reported in adults ≥18 years of age.1 In addition, adverse effects reported in pediatric trials are similar to those reported in adult trials.1

Geriatric Use

No substantial differences in safety and efficacy relative to younger adults.1

Substantially eliminated by kidneys; consider age-related decreases in renal function, select dosage with caution, and consider monitoring renal function.1 (See Renal Impairment under Dosage and Administration.)

Hepatic Impairment

Pharmacokinetics not established; systemic clearance not expected to be altered by hepatic impairment.1

Renal Impairment

Dosage adjustments necessary in adults with Clcr ≤50 mL/minute, including those undergoing hemodialysis.1 Data insufficient to date to make dosage recommendations for pediatric patients with Clcr <50 mL/minute per 1.73 m2.1 (See Renal Impairment under Dosage and Administration.)

Common Adverse Effects

Adults: GI effects (diarrhea,1 25 nausea,1 25 vomiting,1 constipation1 ), headache,25 rash,1 25 pruritus,25 hypokalemia,1 increased transaminases,1 25 phlebitis.1

Children 2 months to <18 years of age: GI effects (diarrhea,1 nausea,1 vomiting1 ), pyrexia,1 rash.1

Interactions for Teflaro

Does not inhibit CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 3A4 in vitro; does not induce CYP1A2, 2B6, 2C8, 2C9, 2C19, or 3A4/5.1 Pharmacokinetic interactions with drugs metabolized by these isoenzymes unlikely.1

No formal drug interaction studies to date.1 Interactions unlikely with CYP substrates, inhibitors, or inducers or drugs that undergo active renal secretion or alter renal blood flow.1

Specific Drugs

Drug

Interaction

Aminoglycosides

Amikacin: In vitro evidence of synergistic antibacterial effects against E. coli and K. pneumoniae that produce extended-spectrum β-lactamases (ESBL-producing), AmpC-derepressed Enterobacter cloacae, and Pseudomonas aeruginosa;22 no evidence of antagonism1 22

Aztreonam

In vitro evidence of indifferent antibacterial effects against ESBL-producing E. coli and K. pneumoniae, AmpC-derepressed E. cloacae, and Ps. aeruginosa;22 no evidence of synergism22 or antagonism1 22

Carbapenems (meropenem)

Meropenem: In vitro evidence of synergistic antibacterial effects against ESBL-producing E. coli and indifferent antibacterial effects against ESBL-producing K. pneumoniae, AmpC-derepressed E. cloacae, and Ps. aeruginosa;22 no evidence of antagonism1 22

Daptomycin

No in vitro evidence of antagonistic antibacterial effects1

Linezolid

No in vitro evidence of antagonistic antibacterial effects1

Macrolides (azithromycin)

Azithromycin: No in vitro evidence of antagonistic antibacterial effects1

Quinolones (levofloxacin)

Levofloxacin: No in vitro evidence of antagonistic antibacterial effects1

Tigecycline

No in vitro evidence of antagonistic antibacterial effects1

Vancomycin

No in vitro evidence of antagonistic antibacterial effects1

Warfarin

Increased PT and elevated INR reported35

Teflaro Pharmacokinetics

Absorption

Ceftaroline is administered as ceftaroline fosamil, a prodrug that is inactive until converted in vivo to ceftaroline by a plasma phosphatase.1 4

Plasma Concentrations

In healthy adults, peak plasma concentrations and AUC increase approximately in proportion to dose following single IV doses of 50–1000 mg of ceftaroline fosamil.1

No appreciable accumulation reported when 600-mg doses are given by IV infusion over 1 hour every 12 hours for up to 14 days in adults with normal renal function.1

Following 600-mg doses in 50 mL of compatible infusion solution given by IV infusion every 8 hours for 5 days in healthy adults, mean peak plasma concentrations were 32.5 mcg/mL when given as a 5-minute infusion and 17.4 mcg/mL when given as a 60-minute infusion;1 time to peak plasma concentrations and AUC were similar for both infusion rates.1

Special Populations

In healthy adolescents 12–17 years of age, peak plasma concentrations and AUC after a single 8-mg/kg IV dose (600 mg in those weighing >75 kg) are 10 and 23% lower, respectively, compared with healthy adults who received a single 600-mg IV dose.1

Distribution

Extent

Limited data available regarding tissue distribution; animal data indicate ceftaroline is distributed into kidneys, skin, and lungs.4 9

Not known whether distributed into milk.1

Plasma Protein Binding

Approximately 20%;1 decreases slightly with increasing concentrations >1–50 mcg/mL.1

Elimination

Metabolism

Ceftaroline fosamil is rapidly converted in vivo to ceftaroline by a plasma phosphatase, principally during IV infusion.1 4 In addition, the β-lactam ring of ceftaroline is hydrolyzed to an inactive, open-ring metabolite (ceftaroline M-1).1

Ceftaroline is not a substrate of CYP isoenzymes.1

Elimination Route

Ceftaroline and its metabolites principally eliminated in urine by glomerular filtration.1 Following a single 600-mg IV dose of ceftaroline fosamil, approximately 88% is eliminated in urine (approximately 64% as unchanged drug, and 2% as ceftaroline M-1) and 6% is eliminated in feces within 48 hours.1

Removed by hemodialysis.1

Half-life

Adults: 2.7 hours.1

Following 600-mg doses of ceftaroline fosamil in 50 mL of compatible infusion solution given by IV infusion over 5 or 60 minutes every 8 hours for 5 days, terminal elimination half-life of ceftaroline was similar for both infusion rates.1

Special Populations

Pediatric patients 2 months to <18 years of age: Pharmacokinetics are similar to pharmacokinetics reported in adults.1

Hepatic impairment: Pharmacokinetics not established.1

Renal impairment: AUC and half-life increased.1 4

Stability

Storage

Parenteral

Powder for IV Infusion

25°C (may be exposed to 15–30°C).1

Following reconstitution and dilution, may be stored in IV infusion bag for up to 6 hours at room temperature or up to 24 hours when refrigerated at 2–8°C.1

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Solution Compatibility1 HID

Compatible

Dextrose 2.5 or 5% in water

Ringer’s injection, lactated

Sodium chloride 0.45 or 0.9%

Drug CompatibilityHID
Y-Site Compatibility

Compatible

Acyclovir sodium

Amikacin sulfate

Aminophylline

Amiodarone HCl

Azithromycin

Bumetanide

Calcium chloride

Calcium gluconate

Ciprofloxacin

Cisatracurium besylate

Clindamycin phosphate

Co-trimoxazole

Cyclosporine

Dexamethasone sodium phosphate

Digoxin

Diltiazem HCl

Diphenhydramine HCl

Dopamine HCl

Doripenem

Enalaprilat

Esomeprazole sodium

Famotidine

Fentanyl citrate

Fluconazole

Furosemide

Gentamicin sulfate

Granisetron HCl

Haloperidol lactate

Heparin sodium

Hydrocortisone sodium succinate

Hydromorphone HCl

Hydroxyzine HCl

Insulin, regular

Levofloxacin

Lidocaine HCl

Lorazepam

Mannitol

Meperidine HCl

Methylprednisolone sodium succinate

Metoclopramide HCl

Metoprolol tartrate

Metronidazole

Midazolam HCl

Milrinone lactate

Morphine sulfate

Moxifloxacin HCl

Multivitamins

Norepinephrine bitartrate

Ondansetron HCl

Pantoprazole sodium

Potassium chloride

Promethazine HCl

Propofol

Ranitidine HCl

Remifentanil HCl

Sodium bicarbonate

Tobramycin sulfate

Vasopressin

Voriconazole

Incompatible

Amphotericin B

Caspofungin acetate

Diazepam

Filgrastim

Labetalol HCl

Potassium phosphates

Sodium phosphates

Variable

Dobutamine HCl

Magnesium sulfate

Actions and Spectrum

  • Based on spectrum of activity, classified as a fifth generation cephalosporin.5 6 7 8 27

  • Like third and fourth generation cephalosporins, ceftaroline has an expanded spectrum of activity that includes both gram-positive and gram-negative bacteria.4 5 6 7 17 21 27 Unlike first, second, third, and fourth generation cephalosporins, ceftaroline has activity against methicillin-resistant S. aureus (MRSA; also known as oxacillin-resistant Staphylococcus aureus, ORSA).4 5 6 7 17 27

  • Usually bactericidal.1 4 17 22

  • Like other β-lactam antibiotics, antibacterial activity results from inhibition of bacterial cell wall synthesis.1

  • Spectrum of activity includes many gram-positive and gram-negative aerobic bacteria1 4 17 18 19 20 21 24 27 and some anaerobic bacteria.23

  • Gram-positive aerobes: Active in vitro against S. aureus (including MRSA, vancomycin-resistant S. aureus [VRSA], and daptomycin-nonsusceptible S. aureus),1 4 17 21 24 27 37 39 41 42 coagulase-negative staphylococci (including methicillin-resistant [oxacillin-resistant] strains),4 21 27 Streptococcus pneumoniae (including penicillin- or cefotaxime-resistant S. pneumoniae or multidrug-resistant S. pneumoniae [MDRSP]),1 4 18 19 20 21 24 27 S. pyogenes (group A β-hemolytic streptococci, GAS),1 4 21 27 42 S. agalactiae (group B streptococci, GBS),1 4 21 27 42 viridans streptococci,4 21 27 and S. dysgalactiae.1 42 Has only limited activity against Enterococcus faecalis; E. faecium are resistant.4 21

  • Gram-negative aerobes: Active in vitro against some Escherichia coli,1 21 27 42 Klebsiella pneumoniae,1 21 27 42 K. oxytoca,1 42 and Haemophilus influenzae (including β-lactamase-producing strains).1 4 21 27 Also active in vitro against some Citrobacter freundii,1 21 27 42 C. koseri,1 Enterobacter aerogenes,1 27 42 E. cloacae,1 21 27 42 Moraxella catarrhalis (including β-lactamase-producing strains),1 4 21 27 Morganella morganii,1 21 42 Pasteurella multocida,21 Proteus mirabilis,1 21 27 42 and H. parainfluenzae.1 Inactive against Pseudomonas aeruginosa.4 27

  • MRSA with reduced susceptibility or resistance to ceftaroline have been produced in vitro40 and reported in clinical isolates.37 38 39 41

  • Gram-negative bacteria that produce extended-spectrum β-lactamases (ESBLs) from the TEM, SHV or CTX-M families, AmpC cephalosporinases, class B metallo-β-lactamases, or serine carbapenemases are resistant.1 4 21 27

  • Although cross-resistance may occur between ceftaroline and other cephalosporins, some bacteria resistant to other cephalosporins may be susceptible to ceftaroline.1

Advice to Patients

  • Advise patients that antibacterials (including ceftaroline) should only be used to treat bacterial infections and not used to treat viral infections (e.g., the common cold).1

  • Importance of completing full course of therapy, even if feeling better after a few days.1

  • Advise patients that skipping doses or not completing the full course of therapy may decrease effectiveness and increase the likelihood that bacteria will develop resistance and will not be treatable with ceftaroline or other antibacterials in the future.1

  • Advise patients that diarrhea is a common problem caused by anti-infectives and usually resolves when the drug is discontinued.1 Importance of contacting a clinician if watery or bloody diarrhea occurs.1

  • Importance of informing clinicians of prior hypersensitivity reactions to ceftaroline, other cephalosporins, other β-lactam antibiotics, or other allergens.1 Importance of discontinuing the drug and immediately informing clinician if an allergic or hypersensitivity reaction occurs.1

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.1

  • Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.1

  • Importance of informing patients of other important precautionary information.1 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Ceftaroline Fosamil

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Parenteral

For injection, for IV infusion

400 mg

Teflaro

Forest

600 mg

Teflaro

Forest

AHFS DI Essentials. © Copyright 2016, Selected Revisions October 4, 2016. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

References

1. Forest Pharmaceuticals, Inc. Teflaro (ceftaroline fosamil) for injection prescribing information. St. Louis, MO; 2016 May.

2. Corey GR, Wilcox M, Talbot GH et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010; 51:641-50. [PubMed 20695801]

3. File TM, Low DE, Eckburg PB et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010; 51:1395-405. [PubMed 21067350]

4. Zhanel GG, Sniezek G, Schweizer F et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Drugs. 2009; 69:809-31. [PubMed 19441869]

5. Kollef MH. New antimicrobial agents for methicillin-resistant Staphylococcus aureus. Crit Care Resusc. 2009; 11:282-6. [PubMed 20001879]

6. Skrupky LP, Micek ST, Kollef MH. Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unit. Crit Care. 2009; 13:222. [PubMed 19889197]

7. Ritchie DJ, Alexander BT, Finnegan PM. New antimicrobial agents for use in the intensive care unit. Infect Dis Clin North Am. 2009; 23:665-81. [PubMed 19665089]

8. Schirmer PL, Deresinski SC. Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections. Expert Rev Anti Infect Ther. 2009; 7:777-91. [PubMed 19735220]

9. US Food and Drug Administration, Center for Drug Evaluation and Research. Pharmacology review(s) NDA application number 200327. From FDA website.

12. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31:431-55. [PubMed 20307191]

13. Fekety R for the American College of Gastroenterology Practice Parameters Committee. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol. 1997; 92:739-50. [IDIS 386628] [PubMed 9149180]

14. American Society of Health-System Pharmacists Commission on Therapeutics. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health-Syst Pharm. 1998; 55:1407-11. [IDIS 407213] [PubMed 9659970]

15. Bauer MP, Kuijper EJ, van Dissel JT et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009; 15:1067-79. [PubMed 19929973]

16. Jaber MR, Olafsson S, Fung WL et al. Clinical review of the management of fulminant Clostridium difficile infection. Am J Gastroenterol. 2008; 103:3195-203; quiz 3204. [PubMed 18853982]

17. Saravolatz L, Pawlak J, Johnson L. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2010; 54:3027-30. [PubMed 20404122]

18. Jacobs MR, Good CE, Windau AR et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 2010; 54:2716-9. [PubMed 20308374]

19. McGee L, Biek D, Ge Y et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2009; 53:552-6. [PubMed 19015339]

20. Fenoll A, Aguilar L, Robledo O et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother. 2008; 52:4209-10. [PubMed 18725443]

21. Ge Y, Biek D, Talbot GH et al. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother. 2008; 52:3398-407. [PubMed 18625769]

22. Vidaillac C, Leonard SN, Sader HS et al. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009; 53:2360-6. [PubMed 19349512]

23. Citron DM, Tyrrell KL, Merriam CV et al. In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob Agents Chemother. 2010; 54:1627-32. [PubMed 20100877]

24. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010; 54:1670-7. [PubMed 20194704]

25. Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010; 65 Suppl 4:iv67-iv71. [PubMed 21115456]

26. Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother. 2010; 65:713-6. [PubMed 20097788]

27. Andes DR, Craig WA. Cephalosporins. In: Mandell GL, Bennett JE, Dolin R eds. Mandell, Douglas and Bennett’s principles and practices of infectious disease. 7th ed. New York: Churchill Livingstone; 2010:323-36.

30. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44 Suppl 2:S27-72. [PubMed 17278083]

31. Bradley JS, Byington CL, Shah SS et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011; 53:e25-76.

32. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011; 52:e18-55. [PubMed 21208910]

33. LaVie KW, Anderson SW, O'Neal HR et al. Neutropenia associated with long-term ceftaroline use. Antimicrob Agents Chemother. 2015; 60:264-9. [PubMed 26503657]

34. Varada NL, Sakoulas G, Lei LR et al. Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin. Pharmacotherapy. 2015; 35:608-12. [PubMed 26037689]

35. Farhat NM, Hutchinson LS, Peters M. Elevated International Normalized Ratio values in a patient receiving warfarin and ceftaroline. Am J Health Syst Pharm. 2016; 73:56-9. [PubMed 26721534]

36. Bhattacharya S, Parekh S, Dedhiya M. In-use Stability of ceftaroline fosamil in elastomeric home infusion systems and MINI-BAG Plus containers. Int J Pharm Compd. 2015 Sep-Oct; 19:432-6. [PubMed 26775451]

37. Biedenbach DJ, Hoban DJ, Reiszner E et al. In vitro activity of ceftaroline against Staphylococcus aureus isolates collected in 2012 from Latin American countries as part of the AWARE surveillance program. Antimicrob Agents Chemother. 2015; 59:7873-7. [PubMed 26416860]

38. Schaumburg F, Peters G, Alabi A et al. Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA. J Antimicrob Chemother. 2016; 71:41-4. [PubMed 26443816]

39. Abbott IJ, Jenney AW, Jeremiah CJ et al. Reduced in vitro activity of ceftaroline by Etest among clonal complex 239 methicillin-resistant staphylococcus aureus clinical strains from Australia. Antimicrob Agents Chemother. 2015; 59:7837-41. [PubMed 26392488]

40. Chan LC, Basuino L, Diep B et al. Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2015; 59:2960-3. [PubMed 25753637]

41. Biedenbach DJ, Alm RA, Lahiri SD et al. In vitro activity of ceftaroline against Staphylococcus aureus isolated in 2012 from Asia-Pacific countries as part of the AWARE surveillance program. Antimicrob Agents Chemother. 2015; 60:343-7. [PubMed 26503659]

42. Hoban D, Biedenbach D, Sahm D et al. Activity of ceftaroline and comparators against pathogens isolated from skin and soft tissue infections in Latin America - results of AWARE surveillance 2012. Braz J Infect Dis. 2015 Nov-Dec; 19:596-603. [PubMed 26481631]

43. Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014; 59:147-59. [PubMed 24947530]

HID. ASHP’s interactive handbook on injectable drugs. McEvoy, GK, ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc; Updated [Jan 12, 2015]. From HID website

Hide